Literature DB >> 2168143

Inhibitory effects of atropine, protamine, and their combination on hepatitis A virus replication in PLC/PRF/5 cells.

E Biziagos1, J M Crance, J Passagot, R Deloince.   

Abstract

Atropine, protamine, and the combination of these drugs were tested for their effects on hepatitis A virus (HAV) replication in cell culture. PLC/PRF/5 hepatoma cells were treated simultaneously with nontoxic concentrations of these drugs and inoculated with HAV strain CF 53 at several multiplicities of infection. The yields of infectious HAV after 4 and 15 days were markedly reduced by each drug, especially at the lowest multiplicity of infection. The activities of each drug were irreversible. Atropine was active when it was added as late as 2 h after inoculation with HAV. An anti-HAV effect was also induced by treating cells with atropine prior to inoculation. Protamine was active as late as 6 h postinoculation. The combination of atropine and protamine resulted in an enhanced anti-HAV effect. We concluded that these drugs affect undetermined, but separate, steps in the HAV replication cycle.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2168143      PMCID: PMC171767          DOI: 10.1128/AAC.34.6.1112

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice.

Authors:  R F Schinazi; J Peters; C C Williams; D Chance; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

2.  Protamine--a potent inhibitor of vesicular stomatitis virus transcriptase in vitro.

Authors:  S Talib; A K Banerjee
Journal:  Biochem Biophys Res Commun       Date:  1981-02-12       Impact factor: 3.575

3.  A method for testing for synergy with any number of agents.

Authors:  M C Berenbaum
Journal:  J Infect Dis       Date:  1978-02       Impact factor: 5.226

4.  Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2.

Authors:  N K Ayisi; V S Gupta; J B Meldrum; A K Taneja; L A Babiuk
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

5.  Evaluation of the anti-herpesvirus drug combinations: virazole plus arabinofuranosylhypoxanthine and virazole plus arabinofuranosyladenine.

Authors:  L B Allen; L K Vanderslice; C M Fingal; F H McCright; E F Harris; P D Cook
Journal:  Antiviral Res       Date:  1982-09       Impact factor: 5.970

6.  Enhancement of activity against influenza viruses by combinations of antiviral agents.

Authors:  F G Hayden; R G Douglas; R Simons
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

7.  Antiviral effects of atropine and caffeine.

Authors:  Z Yamazaki; I Tagaya
Journal:  J Gen Virol       Date:  1980-10       Impact factor: 3.891

8.  Failure of guanidine and 2-(alpha-hydroxybenzyl)benzimidazole to inhibit replication of hepatitis A virus in vitro.

Authors:  G Siegl; H J Eggers
Journal:  J Gen Virol       Date:  1982-07       Impact factor: 3.891

Review 9.  Protamine--antagonist to heparin.

Authors:  L B Jaques
Journal:  Can Med Assoc J       Date:  1973-05-19       Impact factor: 8.262

10.  Acute hepatitis A, B and non-A, non-B in a Swedish community studied over a ten-year period.

Authors:  A Widell; B G Hansson; T Moestrup; Z Serléus; L R Mathiesen; T Johnsson
Journal:  Scand J Infect Dis       Date:  1982
View more
  2 in total

Review 1.  Cell Culture Systems and Drug Targets for Hepatitis A Virus Infection.

Authors:  Tatsuo Kanda; Reina Sasaki; Ryota Masuzaki; Naoki Matsumoto; Masahiro Ogawa; Mitsuhiko Moriyama
Journal:  Viruses       Date:  2020-05-12       Impact factor: 5.048

Review 2.  Molecular biology and inhibitors of hepatitis A virus.

Authors:  Yannick Debing; Johan Neyts; Hendrik Jan Thibaut
Journal:  Med Res Rev       Date:  2013-05-30       Impact factor: 12.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.